Nihal E. Mohamed 1 , Emma K. T. Benn 2 , Varuna Astha 2 , Kennedy E. Okhawere 1 , Talia G. Korn 1 , William Nkemdirim 1 , Ami Rambhia 1 , Olajumoke A. Ige 1 , Hassan Funchess 1 , Meredith Mihalopoulos 1 , Kirolos N. Meilika 1 , Natasha Kyprianou 1 , 3 , 4 , Ketan K. Badani , 1 , 3
22 January 2021
To evaluate mortality risk of CKD patients infected with COVID-19, and assess shared characteristics associated with health disparities in CKD outcome.
We extracted the data from a case series of 7624 patients presented at Mount Sinai Health System, in New York for testing between 3/28/2020 and 4/16/2020. De-identified patient data set is being produced by the Scientific Computing department and made available to the Mount Sinai research community at the following website: https://msdw.mountsinai.org/.
Of 7624 COVID-19 patients, 7.8% ( n = 597) had CKD on hospital admission, and 11.2% ( n = 856) died of COVID-19 infection. CKD patients were older, more likely to have diabetes, hypertension, and chronic obstructive pulmonary disease (COPD), were current or former smokers, had a longer time to discharge, and had worse survival compared to non-CKD patients ( p < 0.05). COVID-19 mortality rate was significantly higher in CKD patients (23.1% vs 10.2%) with a 1.51 greater odds of dying (95% CI: 1.19–1.90). Controlling for demographic, behavioral, and clinical covariates, the logistic regression analysis showed significant and consistent effects of CKD, older age, male gender, and hypertension with mortality ( p < 0.05).